| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040378214 |
| P356 | DOI | 10.1038/SJ.ONC.1204265 |
| P698 | PubMed publication ID | 11360182 |
| P5875 | ResearchGate publication ID | 11978315 |
| P2093 | author name string | Chen T | |
| Charboneau L | |||
| Emmert-Buck MR | |||
| Gillespie JW | |||
| Liotta LA | |||
| Paweletz CP | |||
| Simone NL | |||
| Bichsel VE | |||
| Roth MJ | |||
| Petricoin III EF | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions | Q24793110 | ||
| Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B | Q27860731 | ||
| Quantitative monitoring of gene expression patterns with a complementary DNA microarray | Q27861102 | ||
| Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation | Q28131755 | ||
| Phosphorylation and regulation of Raf by Akt (protein kinase B) | Q28138863 | ||
| Laser capture microdissection | Q28293867 | ||
| High density synthetic oligonucleotide arrays | Q29616560 | ||
| Tissue microarrays for high-throughput molecular profiling of tumor specimens | Q29618675 | ||
| Protein microarrays for gene expression and antibody screening | Q30699824 | ||
| Large-scale functional analysis using peptide or protein arrays. | Q30854444 | ||
| Microminiaturized immunoassays using atomic force microscopy and compositionally patterned antigen arrays | Q32066938 | ||
| UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions | Q33613520 | ||
| Light-directed, spatially addressable parallel chemical synthesis | Q35012280 | ||
| Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties | Q36546865 | ||
| Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression | Q40877541 | ||
| PI3K: downstream AKTion blocks apoptosis | Q41351876 | ||
| Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat. | Q42489437 | ||
| Rap1 mediates sustained MAP kinase activation induced by nerve growth factor | Q42830846 | ||
| Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway | Q47762057 | ||
| Kinetic profiles of intraepithelial and invasive prostatic neoplasias: the key role of down-regulated apoptosis in tumor progression. | Q64889885 | ||
| Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor | Q72121269 | ||
| Array biosensor for simultaneous identification of bacterial, viral, and protein analytes | Q72998057 | ||
| Akt takes center stage in angiogenesis signaling | Q73333632 | ||
| Protein microchips: use for immunoassay and enzymatic reactions | Q73413695 | ||
| Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation | Q73843666 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tumor invasion | Q60750433 |
| medical invasion front | Q112158087 | ||
| P304 | page(s) | 1981-1989 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front | |
| P478 | volume | 20 |
| Q37142857 | -Omics and cancer biomarkers: link to the biological truth or bear the consequences |
| Q35940178 | A Multi-Method Approach for Proteomic Network Inference in 11 Human Cancers |
| Q35049524 | A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers |
| Q30867943 | A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data |
| Q34401036 | A critical comparison of protein microarray fabrication technologies |
| Q33621880 | A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. |
| Q30414621 | A high-throughput assay for phosphoprotein-specific phosphatase activity in cellular extracts |
| Q37898108 | A new frontier in personalized cancer therapy: mapping molecular changes. |
| Q81126960 | A nondestructive molecule extraction method allowing morphological and molecular analyses using a single tissue section |
| Q41812378 | A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum |
| Q35916012 | A perspective on DNA microarrays in pathology research and practice |
| Q37423291 | A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer |
| Q34478770 | A pilot characterization of human lung NSCLC by protein pathway activation mapping |
| Q36186223 | A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. |
| Q36919993 | A portrait of tissue phosphoprotein stability in the clinical tissue procurement process |
| Q46780069 | A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib |
| Q45052926 | A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation |
| Q93112495 | A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia |
| Q37040615 | A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas |
| Q33764388 | A well-based reverse-phase protein array applicable to extracts from formalin-fixed paraffin-embedded tissue. |
| Q33239131 | AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies |
| Q28396602 | Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters |
| Q37184559 | Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response |
| Q37711623 | Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer |
| Q36092560 | Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance |
| Q33608593 | Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes |
| Q30429122 | Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial |
| Q36112651 | Advances in Proteomic Technologies and Its Contribution to the Field of Cancer |
| Q35551113 | Advantages and limitations of microarray technology in human cancer |
| Q64074466 | Alterations in Phosphorylation of Hepatocyte Ribosomal Protein S6 Control Plasmodium Liver Stage Infection |
| Q53671747 | An 8 minute colorimetric paper-based reverse phase vertical flow serum microarray for screening of hyper IgE syndrome. |
| Q58748144 | An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease |
| Q38560159 | An overview of innovations and industrial solutions in Protein Microarray Technology. |
| Q58197405 | Analyse von Signalwegen in formalinfixierten Brustkrebsgeweben |
| Q37727184 | Analysis of NF-kappaB signaling pathways by proteomic approaches |
| Q28080766 | Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery |
| Q35749794 | Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases |
| Q30956643 | Antibodies in proteomics II: screening, high-throughput characterization and downstream applications |
| Q57952030 | Antibody and Reverse Capture Protein Microarrays for Clinical Proteomics |
| Q36020258 | Antibody arrays in cancer research |
| Q37622475 | Antibody-based proteomics: analysis of signaling networks using reverse protein arrays |
| Q34132010 | Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. |
| Q47289799 | Apoptosis in cancer: archaeology, functional relevance and exploitation in novel treatment strategies |
| Q33203895 | Application of laser capture microdissection and protein microarray technologies in the molecular analysis of airway injury following pollution particle exposure |
| Q38194417 | Application of molecular technologies for phosphoproteomic analysis of clinical samples |
| Q37219904 | Application of physicochemically modified silicon substrates as reverse-phase protein microarrays |
| Q25257533 | Application of protein lysate microarrays to molecular marker verification and quantification |
| Q37790704 | Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy |
| Q35976410 | Application of proteomic technologies to tumor analysis |
| Q35170387 | Applications of protein microarrays for biomarker discovery |
| Q38255299 | Array-based proteomic approaches to study signal transduction pathways: prospects, merits and challenges |
| Q30503288 | Asymmetric cancer cell division regulated by AKT |
| Q37173785 | Automated analytical microarrays: a critical review. |
| Q30985471 | BAYESIAN SPARSE GRAPHICAL MODELS FOR CLASSIFICATION WITH APPLICATION TO PROTEIN EXPRESSION DATA. |
| Q58036015 | Bacteria microarrays as sensitive tools for exploring pathogen surface epitopes and recognition by host receptors |
| Q92616665 | Bayesian Hierarchical Varying-sparsity Regression Models with Application to Cancer Proteogenomics |
| Q35598455 | Biochips beyond DNA: technologies and applications |
| Q36590935 | Biomarkers in cancer screening, research and detection: present and future: a review. |
| Q28278305 | Biomarkers in cancer staging, prognosis and treatment selection |
| Q34989344 | Biomedical applications of protein chips. |
| Q33344833 | Blocking and detection chemistries affect antibody performance on reverse phase protein arrays |
| Q39644047 | Blocking of PI3K/AKT induces apoptosis by its effect on NF-κB activity in gastric carcinoma cell line SGC7901 |
| Q37684550 | CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. |
| Q37307199 | Cancer biomarkers: are we ready for the prime time? |
| Q36279065 | Cancer proteomics: many technologies, one goal |
| Q89000005 | Cell Lysate Microarray for Mapping the Network of Genetic Regulators for Histone Marks |
| Q36227928 | Challenges facing the development and use of protein chips to analyze the phosphoproteome |
| Q35623336 | Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells |
| Q35201471 | Chromosome aberrations in solid tumors |
| Q37605790 | Clinical application of proteomics in ovarian cancer prevention and treatment |
| Q30893390 | Clinical proteomics for cancer biomarker discovery and therapeutic targeting |
| Q33999524 | Clinical proteomics of myeloid leukemia |
| Q36960733 | Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective |
| Q38320931 | Clinical proteomics: promises, challenges and limitations of affinity arrays |
| Q34810370 | Clinical proteomics: translating benchside promise into bedside reality |
| Q36371264 | Clustering and Network Analysis of Reverse Phase Protein Array Data |
| Q31068816 | Collecting and organizing systematic sets of protein data |
| Q38353668 | Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer |
| Q35080706 | Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer |
| Q33720256 | Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo |
| Q34336095 | Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues |
| Q35848973 | Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma |
| Q30893357 | Contributions of proteome profiling to the molecular analysis of cancer |
| Q36686826 | Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer |
| Q34014956 | Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. |
| Q35812532 | Development and use of biomarkers in oncology drug development |
| Q38317785 | Development of a microscopic platform for real-time monitoring of biomolecular interactions |
| Q41469375 | Development of a novel proteomic approach for mitochondrial proteomics from cardiac tissue from patients with atrial fibrillation |
| Q35221345 | Development of a robust classifier for quality control of reverse-phase protein arrays |
| Q33427212 | Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker |
| Q24562089 | Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells |
| Q34904008 | Dimensionality is the issue: use of photoaptamers in protein microarrays |
| Q38293886 | Discovering cancer biomarkers from clinical samples by protein microarrays |
| Q28744610 | Discovery of new molecular subtypes in oesophageal adenocarcinoma |
| Q35084579 | Disease proteomics |
| Q39009610 | Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma |
| Q37574617 | Dissecting protein function and signaling using protein microarrays. |
| Q35595698 | Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. |
| Q40205540 | Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray |
| Q53583157 | Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia. |
| Q40439945 | Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation |
| Q36161077 | Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype |
| Q38821536 | Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis. |
| Q38966416 | Dual-Color, Multiplex Analysis of Protein Microarrays for Precision Medicine |
| Q56543288 | Efficient Management of High-Throughput Screening Libraries with SAVANAH |
| Q30439048 | Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors |
| Q36241222 | Elevated expression levels of ANXA11, integrins β3 and α3, and TNF-α contribute to a candidate proteomic signature in urine for kidney allograft rejection |
| Q37610324 | Emerging affinity-based techniques in proteomics |
| Q26824107 | Emerging protein array technologies for proteomics |
| Q38090648 | Entering the era of proteomics in rheumatology. |
| Q36134032 | Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA) |
| Q38823921 | Evaluation of Solid Supports for Slide- and Well-Based Recombinant Antibody Microarrays |
| Q47241083 | Evaluation of apoptotic- and autophagic-related protein expressions before and after IVM of fresh, slow-frozen and vitrified pre-pubertal mouse testicular tissue |
| Q35675442 | Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. |
| Q53605156 | Expression of insulin-like growth factor-1 receptor, p-AKT and p-ERK1/2 protein in extramammary Paget's disease. |
| Q26864708 | Facing current quantification challenges in protein microarrays |
| Q74794924 | Factors influencing cDNA microarray hybridization on silylated glass slides |
| Q35197881 | Free radical functionalization of surfaces to prevent adverse responses to biomedical devices |
| Q32114300 | From combinatorial chemistry to chemical microarray |
| Q30765248 | Functional genomics studied by proteomics. |
| Q27025953 | Functional protein microarray as molecular decathlete: a versatile player in clinical proteomics |
| Q34517733 | Functional protein microarrays |
| Q34184598 | Functional proteomic profiling of AML predicts response and survival |
| Q34974770 | Functional proteomics to study protection of the ischaemic myocardium |
| Q24798750 | Genetic alteration and gene expression modulation during cancer progression |
| Q37526789 | Genomic approaches to outcome prediction in prostate cancer |
| Q35134364 | Genomics and proteomics in cancer |
| Q78511667 | Genomics and proteomics: application of novel technology to early detection and prevention of cancer |
| Q30414265 | Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition |
| Q36097185 | High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancer |
| Q35098555 | High resolution mapping of the cardiac transmural proteome using reverse phase protein microarrays |
| Q48733544 | High-Density Serum/Plasma Reverse Phase Protein Arrays. |
| Q35735913 | Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients |
| Q37727189 | Histo-proteomic profiling of formalin-fixed, paraffin-embedded tissue. |
| Q50101328 | Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors |
| Q31140924 | How may targeted proteomics complement genomic data in breast cancer? |
| Q36766852 | How to comprehensively analyse proteins and how this influences nutritional research |
| Q28476327 | Human cell chips: adapting DNA microarray spotting technology to cell-based imaging assays |
| Q34605232 | Identification of novel targets for cancer therapy using expression proteomics |
| Q36519000 | Immunocapture strategies in translational proteomics. |
| Q30449408 | Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples |
| Q47592965 | Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer |
| Q42710867 | Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification |
| Q38092886 | Individualized therapy for metastatic colorectal cancer. |
| Q33965489 | Inferring signalling networks from longitudinal data using sampling based approaches in the R-package 'ddepn' |
| Q40169465 | Infrared-based protein detection arrays for quantitative proteomics |
| Q39141522 | Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells |
| Q40072022 | Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response |
| Q35804471 | Integrated molecular profiling of SOD2 expression in multiple myeloma |
| Q37691056 | Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations |
| Q35142185 | Integrating microarrays into disease-gene identification strategies |
| Q104473838 | Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies |
| Q37643449 | Integrin signaling aberrations in prostate cancer. |
| Q39826121 | Interaction of Snail and p38 mitogen-activated protein kinase results in shorter overall survival of ovarian cancer patients |
| Q33226260 | Kinetics of cardiac thin-filament activation probed by fluorescence polarization of rhodamine-labeled troponin C in skinned guinea pig trabeculae |
| Q44036972 | Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma |
| Q38088851 | Large-scale studies to identify biomarkers for heart disease: a role for proteomics? |
| Q33358603 | Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type |
| Q47757910 | Laser capture microdissection for proteome analysis |
| Q28250373 | Laser capture microdissection technology |
| Q60673340 | Laser-capture microdissection |
| Q34439395 | Linking signaling pathways to transcriptional programs in breast cancer. |
| Q46083468 | Longitudinal Monitoring of Antibody Responses against Tumor Cells Using Magneto-nanosensors with a Nanoliter of Blood |
| Q40029092 | Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. |
| Q34751674 | Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling |
| Q38791344 | MAP Kinases and Prostate Cancer |
| Q33565313 | Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival |
| Q33218898 | Manual exfoliation of fresh tissue obviates the need for frozen sections for molecular profiling |
| Q33300676 | Mass spectrometry-based functional proteomics: from molecular machines to protein networks |
| Q34384187 | Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer |
| Q38010665 | Measuring molecular biomarkers in epidemiologic studies: laboratory techniques and biospecimen considerations |
| Q36286117 | Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarray |
| Q35010175 | Medical applications of microarray technologies: a regulatory science perspective |
| Q40126795 | Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells |
| Q34639530 | Metastasis: new perspectives on an old problem |
| Q35574629 | Methods and applications of antibody microarrays in cancer research |
| Q36617361 | Methods for proteomics in neuroscience |
| Q42724150 | MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia |
| Q41942112 | Microarray R-based analysis of complex lysate experiments with MIRACLE. |
| Q37335033 | Microarray methods for protein biomarker detection |
| Q23924056 | Microarray profiling in breast cancer patients |
| Q38105616 | Microarrays and microneedle arrays for delivery of peptides, proteins, vaccines and other applications |
| Q38903529 | Mission Critical: The Need for Proteomics in the Era of Next-Generation Sequencing and Precision Medicine |
| Q36547793 | Modeling of protein signaling networks in clinical proteomics |
| Q35125845 | Modern proteomic strategies in the study of complex neuropsychiatric disorders |
| Q30967609 | Modified SuperCurve Method for Analysis of Reverse-Phase Protein Array Data |
| Q36627755 | Molecular biomarkers for cancer detection in blood and bodily fluids |
| Q36530573 | Molecular biomarkers in glaucoma |
| Q36611417 | Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines |
| Q34127462 | Molecular genetics of prostate cancer: new prospects for old challenges |
| Q42457753 | Morphologically distinct patterns of apoptosis correlate with size and high-grade dysplasia in colonic adenomas |
| Q39234722 | Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays |
| Q36227932 | Multiplex approaches in protein microarray technology. |
| Q34289736 | Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. |
| Q42878950 | NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols |
| Q38514458 | Nanotechnologies in protein microarrays. |
| Q37238431 | New Technologies for Diagnosing Pediatric Tumors Expert Opinion on Medical Diagnostics |
| Q26800283 | New approaches to understanding the immune response to vaccination and infection |
| Q37855302 | New technologies in cancer. Protein microarrays for biomarker discovery |
| Q48395052 | Non-parametric quantification of protein lysate arrays |
| Q34325755 | NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data |
| Q40458882 | Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load. |
| Q34670535 | Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum |
| Q33217470 | Novel proteomic approaches for tissue analysis |
| Q36683880 | Nuclear receptors and the Warburg effect in cancer |
| Q91975074 | Offsetting Expression Profiles of Prognostic Markers in Prostate Tumor vs. Its Microenvironment |
| Q37183820 | Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma |
| Q37801028 | Oncoproteomics |
| Q27323289 | One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens |
| Q42219946 | Opposing activities of oncogenic MIR17HG and tumor suppressive MIR100HG clusters and their gene targets regulate replicative senescence in human adult stem cells. |
| Q26830244 | Overview of protein microarrays |
| Q37073602 | PKC signaling prevents irradiation-induced apoptosis of primary human fibroblasts |
| Q33416583 | Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures |
| Q39671200 | Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors |
| Q54979241 | Personalization of prostate cancer therapy through phosphoproteomics. |
| Q36493303 | Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review |
| Q37779306 | Personalized medicine in oncology: tailoring the right drug to the right patient |
| Q33573142 | Phosphokinase antibody arrays on dendron-coated surface. |
| Q30450696 | Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology |
| Q37261185 | Phosphoproteomic profiling of mouse primary HSPCs reveals new regulators of HSPC mobilization |
| Q34539788 | Phosphoproteomics in cancer |
| Q46420104 | Phosphosite-Specific Antibodies: A Brief Update on Generation and Applications |
| Q36124329 | Physiological mechanisms of tumor-cell invasion and migration |
| Q36802337 | Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways |
| Q28249165 | Porous silicon protein microarray technology and ultra-/superhydrophobic states for improved bioanalytical readout |
| Q40044147 | Porous silicon surfaces: a candidate substrate for reverse protein arrays in cancer biomarker detection |
| Q37294447 | Porphyrin-based photocatalytic nanolithography: a new fabrication tool for protein arrays. |
| Q35010180 | Post-analysis follow-up and validation of microarray experiments |
| Q58197421 | Precise measurement of the E-cadherin repressor Snail in formalin-fixed endometrial carcinoma using protein lysate microarrays |
| Q35024682 | Prediction of individual response to anticancer therapy: historical and future perspectives |
| Q44993889 | Preparation and use of reverse protein microarrays. |
| Q37216951 | Presence of anaplastic lymphoma kinase in inflammatory breast cancer |
| Q57326021 | Profiling metabolic changes in breast cancer with targeted proteomics |
| Q36897569 | Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays |
| Q54605761 | Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR. |
| Q35130207 | Profiling the Global Tyrosine Phosphorylation State |
| Q35648859 | Promising directions for the diagnosis and management of gynecological cancers |
| Q33632268 | Protein Array-based Approaches for Biomarker Discovery in Cancer |
| Q24798712 | Protein and Chemical Microarrays—Powerful Tools for Proteomics |
| Q33213208 | Protein arrays for studying blood cells and their secreted products |
| Q36561644 | Protein biomarker discovery and validation: the long and uncertain path to clinical utility |
| Q47261659 | Protein biomarkers for subtyping breast cancer and implications for future research. |
| Q54239638 | Protein expression profiling during wallerian degeneration after rat sciatic nerve injury. |
| Q35002206 | Protein microarrays and biomarkers of infectious disease |
| Q35010194 | Protein microarrays and proteomics |
| Q36168440 | Protein microarrays as a discovery tool for studying protein-protein interactions |
| Q37791995 | Protein microarrays for genome-wide posttranslational modification analysis. |
| Q46354234 | Protein microarrays for multiplex analysis of signal transduction pathways |
| Q37831719 | Protein microarrays for systems biology |
| Q35574634 | Protein microarrays: Promising tools for proteomic research |
| Q36401458 | Protein microarrays: a chance to study microorganisms? |
| Q34977186 | Protein microarrays: high-throughput tools for proteomics |
| Q34194188 | Protein microarrays: meeting analytical challenges for clinical applications. |
| Q35109872 | Protein microarrays: novel developments and applications |
| Q38708267 | Protein network construction using reverse phase protein array data |
| Q33901255 | Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation |
| Q28259553 | Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines |
| Q54689509 | Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. |
| Q34450771 | Protein-protein interaction predictions using text mining methods |
| Q33792433 | Proteogenomic convergence for understanding cancer pathways and networks |
| Q35917814 | Proteomic analysis of mitochondrial proteins |
| Q35077775 | Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations |
| Q37643312 | Proteomic profiling in ovarian cancer |
| Q42375237 | Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors |
| Q30449558 | Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays |
| Q38765422 | Proteomic profiling predicts drug response to novel targeted anticancer therapeutics |
| Q38184495 | Proteomic strategies for the discovery of novel diagnostic and therapeutic targets for infectious diseases |
| Q33891197 | Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead |
| Q33478412 | Proteomics Discovery of Disease Biomarkers |
| Q38097847 | Proteomics and NF-κB: an update |
| Q28766969 | Proteomics and mass spectrometry for cancer biomarker discovery |
| Q33940880 | Proteomics and mass spectrometry: what have we learned about the heart? |
| Q35791534 | Proteomics for protein expression profiling in neuroscience |
| Q37313554 | Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins |
| Q36478865 | Proteomics technology and therapeutics. |
| Q37771859 | Proteomics: a pragmatic perspective |
| Q40287846 | Protocadherin-PC promotes androgen-independent prostate cancer cell growth. |
| Q36363538 | Quantitative dot blot analysis (QDB), a versatile high throughput immunoblot method |
| Q33697764 | Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer |
| Q58704613 | Quantitative screening of serum protein biomarkers by reverse phase protein arrays |
| Q34500104 | RNAi-based validation of antibodies for reverse phase protein arrays |
| Q33850616 | Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society |
| Q47331651 | Recent Advances in Substrate Identification of Protein Kinases in Plants and Their Role in Stress Management |
| Q39438085 | Recent advances in methods to assess the activity of the kinome |
| Q35714211 | Recent progress in protein profiling of clinical tissues for next-generation molecular diagnostics |
| Q28473351 | Receptor tyrosine kinase (RTK) mediated tyrosine phosphor-proteome from Drosophila S2 (ErbB1) cells reveals novel signaling networks |
| Q28537891 | Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks |
| Q36891562 | Reconstitution of Schwannian stroma in neuroblastomas using human bone marrow stromal cells |
| Q30177456 | Reduced PARP1 as a Serum Biomarker for Graft Rejection in Kidney Transplantation |
| Q47951500 | Reverse Phase Protein Arrays and Drug Discovery |
| Q28083256 | Reverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use |
| Q38787411 | Reverse Phase Protein Microarrays |
| Q57326030 | Reverse phase protein array based tumor profiling identifies a biomarker signature for risk classification of hormone receptor-positive breast cancer |
| Q26799716 | Reverse phase protein arrays in signaling pathways: a data integration perspective |
| Q36519831 | Reverse phase protein arrays: mapping the path towards personalized medicine. |
| Q28384553 | Reverse phase protein microarrays advance to use in clinical trials |
| Q33381529 | Reverse-phase protein lysate microarrays for cell signaling analysis |
| Q36950451 | Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. |
| Q35016599 | SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis |
| Q34320767 | Sequential Multiplex Analyte Capturing for Phosphoprotein Profiling |
| Q33514817 | Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients |
| Q53659324 | Serum microarrays for large scale screening of protein levels. |
| Q57952153 | Serum proteomic signature for cystic fibrosis using an antibody microarray platform |
| Q58206209 | Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition |
| Q33194505 | Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays |
| Q31021936 | Signal pathway profiling of prostate cancer using reverse phase protein arrays |
| Q38809615 | Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients |
| Q31041738 | Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray |
| Q33502309 | Single-cell pathogen detection with a reverse-phase immunoassay on impedimetric transducers |
| Q30877911 | Spatial normalization of reverse phase protein array data |
| Q48869407 | Spatially-resolved protein surface microsampling from tissue sections using liquid extraction surface analysis. |
| Q35809020 | Spatiotemporal expression profiling of proteins in rat sciatic nerve regeneration using reverse phase protein arrays |
| Q30278883 | Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia |
| Q30940949 | Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival |
| Q37132800 | State of the art in tumor antigen and biomarker discovery. |
| Q40228748 | State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling |
| Q47110630 | Statistical Contributions to Bioinformatics: Design, Modeling, Structure Learning, and Integration |
| Q38268585 | Subtyping of breast cancer using reverse phase protein arrays |
| Q91891716 | Super-Enhancer-Associated LncRNA UCA1 Interacts Directly with AMOT to Activate YAP Target Genes in Epithelial Ovarian Cancer |
| Q42540737 | Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots |
| Q37853185 | Systematic antibody and antigen-based proteomic profiling with microarrays |
| Q33896605 | Systems analysis of EGF receptor signaling dynamics with microwestern arrays |
| Q30486190 | TMA Navigator: Network inference, patient stratification and survival analysis with tissue microarray data |
| Q38438756 | Targetable T-type Calcium Channels Drive Glioblastoma |
| Q37945786 | Targeted protein-omic methods are bridging the gap between proteomic and hypothesis-driven protein analysis approaches |
| Q34422523 | Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues |
| Q36841356 | Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model |
| Q39484796 | Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines |
| Q36995054 | Targeting prostate cancer based on signal transduction and cell cycle pathways. |
| Q38034442 | Targeting proteomics to investigate metastasis-associated mitochondrial proteins |
| Q36472432 | Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays |
| Q33289727 | Technology insight: the application of proteomics in gastrointestinal disease |
| Q35185640 | The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities |
| Q44924621 | The blood peptidome: a higher dimension of information content for cancer biomarker discovery |
| Q36388648 | The challenge of analyzing the proteome in humans with autoimmune diseases |
| Q35082260 | The changing role of pathology in breast cancer diagnosis and treatment |
| Q34608851 | The current state of proteomics in GI oncology |
| Q51901383 | The grand challenge to decipher the cancer proteome. |
| Q36660120 | The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease |
| Q29620375 | The microenvironment of the tumour-host interface |
| Q51733574 | The mode and dynamics of glioblastoma cell invasion into a decellularized tissue-derived extracellular matrix-based three-dimensional tumor model. |
| Q38432539 | The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology |
| Q34688223 | The promise of biomarkers in cancer screening and detection |
| Q28645742 | The protein kinase B/Akt signalling pathway in human malignancy |
| Q37998531 | The proteomic toolbox for studying cerebrospinal fluid |
| Q38166249 | The role of glycogen synthase kinase 3-β in immunity and cell cycle: implications in esophageal cancer |
| Q33508672 | The role of proteomics in the diagnosis and treatment of ovarian cancer |
| Q41681563 | The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia |
| Q30361936 | The use of proteomics to identify novel therapeutic targets for the treatment of disease. |
| Q44452599 | Three-Dimensionally Functionalized Reverse Phase Glycoprotein Array for Cancer Biomarker Discovery and Validation. |
| Q35927574 | Towards a systems biology understanding of human health: interplay between genotype, environment and nutrition |
| Q35973576 | Toxicoproteomics: proteomics applied to toxicology and pathology |
| Q46121545 | Trends in microarray analysis |
| Q36347897 | Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype |
| Q28392741 | Udp-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer |
| Q34580473 | Understanding cancer metastasis: an urgent need for using differential gene expression analysis |
| Q37937424 | Unravelling the complexity of metastasis - molecular understanding and targeted therapies |
| Q40271317 | Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation |
| Q33659070 | Update on protein analysis of fixed tissues |
| Q30868541 | Use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis |
| Q33196034 | Use of proteomic analysis to monitor responses to biological therapies |
| Q44454992 | Utility, reliability and reproducibility of immunoassay multiplex kits. |
| Q92830562 | Utilization of Proteomic Technologies for Precision Oncology Applications |
| Q37038561 | Validation and quality control of protein microarray-based analytical methods |
| Q51347842 | Validation of Biomarker Proteins Using Reverse Capture Protein Microarrays. |
| Q34354775 | Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer |
| Q38545364 | Variable slope normalization of reverse phase protein arrays |
| Q35035679 | Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer |
| Q33217474 | What can proteomic analyses contribute to understanding the molecular biology and clinical behavior of prostate cancer? |
| Q37130512 | What is the malignant nature of human ductal carcinoma in situ? |
| Q81488858 | [Rationale for oncological surgery in multimodal cancer treatments] |
| Q38916726 | γ-Oryzanol reduces caveolin-1 and PCGEM1 expression, markers of aggressiveness in prostate cancer cell lines |
Search more.